-+ 0.00%
-+ 0.00%
-+ 0.00%

CELCUITY ANNOUNCES FDA APPROVAL OF REVTORPYK™ (GEDATOLISIB) FOR THE TREATMENT OF HR+/HER2-, PIK3CA WILD-TYPE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Reuters·07/14/2026 20:53:30

Please log in to view news